LexDanaLexDanabeta
Inventor

John F. Kadow

Inventor
Wallingford, CT, US

Overview

134→
Patents
1989–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 134 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
A61KPreparations for medical, dental or toiletry purposes18%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07HSugars2%
C07CAcyclic or carbocyclic compounds2%
C07BGeneral methods of organic chemistry1%
H10WGeneric packages, interconnections, connectors or other constructional details of devices covered by class h101%
B82YSpecific uses or applications of nanostructures0%
PatentTitleYear
10,954,252Inhibitors of human immunodeficiency virus replication202110,577,3535-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication202010,570,108Substituted benzofuran compounds for the treatment of hepatitis C202010,407,410Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication201910,351,546Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication201910,221,156Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication201910,214,534Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C201910,214,5165-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication201910,202,403Macrocyclic benzofuran compounds for the treatment of hepatitis C201910,189,816Substituted pyridines as inhibitors of human immunodeficiency virus replication201910,150,747Compounds for the treatment of hepatitis C201810,138,253Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication201810,131,645Benzofurans substituted with primary benzamide as HCV inhibitors201810,125,137Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors201810,125,111Benzofuran compounds for the treatment of hepatitis C201810,125,148Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication201810,106,504Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication201810,087,167Benzofurans substituted with secondary benzamide as HCV inhibitors20189,957,278Furopyridine compounds for the treatment of hepatitis C20189,938,271Inhibitors of human immunodeficiency virus replication20189,932,356Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication20189,920,036'Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C'20189,914,739'6H-furo[2,3-E]indole compounds for the treatment of hepatitis C'20189,840,511'2-(aryl or heteroaryl-)phenyl (AZA)benzofuran compounds for the treatment of hepatitis C'20179,834,566Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication20179,770,439'Hepatitis C virus inhibitors'20179,655,889'Inhibitors of human immunodeficiency virus replication'20179,655,888'Tricyclic alkene derivatives as HIV attachment inhibitors'20179,586,957'2-keto amide derivatives as HIV attachment inhibitors'20179,546,160'Hepatitis C virus inhibitors'20179,505,752'Piperidine amide derivatives as HIV attachment inhibitors'20169,434,738'Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C'20169,409,922'Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication'20169,326,973'Hepatitis C virus inhibitors'20169,303,020'Compounds for the treatment of hepatitis C'20169,273,067'Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication'20169,249,152'Cyano containing azabenzofuran compounds for the treatment of hepatitis C'20169,193,725'Cyclic hydrazine derivatives as HIV attachment inhibitors'20159,193,720'Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication'20159,156,828'Tricyclic amidine derivatives as HIV attachment inhibitors'20158,962,651'Compounds for the treatment of hepatitis C'20158,912,195'Alkyl amides as HIV attachment inhibitors'20148,906,929'Inhibitors of human immunodeficiency virus replication'20148,871,771'Salts of prodrugs of piperazine and substituted piperidine antiviral agents'20148,835,454'Fused bicyclic diamine derivatives as HIV attachment inhibitors'20148,809,548'Hepatitis C virus inhibitors'20148,796,466'Hepatitis C virus inhibitors'20148,722,688'Compounds for the treatment of hepatitis C'20148,685,982'Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors'20148,664,213'Spiro bicyclic diamine derivatives as HIV attachment inhibitors'20148,552,047'Hepatitis C virus inhibitors'20138,536,338'Compounds for the treatment of hepatitis C'20138,507,683'Compounds for the treatment of hepatitis C'20138,461,333'Salts of prodrugs of piperazine and substituted piperidine antiviral agents'20138,450,361'Substituted indole and azaindole oxoacetyl piperazinamide derivatives'20138,445,497'Compounds for the treatment of hepatitis C'20138,431,568'Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors'20138,354,410'Compounds for the treatment of hepatitis C'20138,324,212'Compounds for the treatment of hepatitis C'20128,309,558'Compounds for the treatment of hepatitis C'20128,293,909'Compounds for the treatment of hepatitis C'20128,198,449'Compounds for the treatment of hepatitis C'20128,178,523'Compounds for the treatment of hepatitis C'20128,168,615'Prodrugs of piperazine and substituted piperidine antiviral agents'20128,148,382'Compounds for the treatment of hepatitis C'20128,143,301'Hepatitis C virus inhibitors'20128,143,414'Hepatitis C virus inhibitors'20128,143,244'Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors'20128,138,171'Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors'20128,124,615'Diketo substituted pyrrolo[2,3-C]pyridines'20128,119,628'Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors'20128,048,887'Compounds for the treatment of hepatitis C'20118,039,486'Indole, azaindole and related heterocyclic N-substituted piperazine derivatives'20117,998,951'HCV NS5B inhibitors'20117,994,171'Compounds for the treatment of hepatitis C'20117,960,406'Diketo substituted pyrrolo[2,3-c] pyridines'20117,915,283'Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides'20117,902,204'Diazaindole-dicarbonyl-piperazinyl antiviral agents'20117,807,671'Diketo-piperazine and piperidine derivatives as antiviral agents'20107,807,676'Diketo-Piperazine and Piperidine derivatives as antiviral agents'20107,745,625'Prodrugs of piperazine and substituted piperidine antiviral agents'20107,745,463'Alkene piperidine derivatives as antiviral agents'20107,714,019'Indole, azaindole and related heterocyclic pyrrolidine derivatives'20107,662,823'Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives'20107,572,810'Alkene piperidine derivatives as antiviral agents'20097,547,690'Compounds for the treatment of Hepatitis C'20097,541,352'Compounds for the treatment of hepatitis C'20097,541,353'Compounds for the treatment of hepatitis C'20097,538,102'Compounds for the treatment of Hepatitis C'20097,531,552'Indole, azaindole and related heterocyclic pyrrolidine derivatives'20097,521,441'Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors'20097,517,872'Compounds for the treatment of hepatitis C'20097,504,399'Piperazine enamines as antiviral agents'20097,501,420'Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives'20097,485,633'Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors'20097,473,688'Indolobenzazepine HCV NS5B inhibitors'20097,452,876'Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors'20087,449,476'Tetrahydrocarboline antiviral agents'20087,399,758'Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors'20087,396,830'Piperazine amidines as antiviral agents'20087,354,924'Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives'20087,348,337'Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides'20087,183,284'Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents'20077,148,220'C-6 modified indazolylpyrrolotriazines'20067,087,610'Benzothiazole antiviral agents'20067,087,621'Benzo- and azabenzodithiazole compounds'20067,037,913'Bicyclo 4.4.0 antiviral derivatives'20066,916,942'Process for the preparation of C-4 carbonate taxanes'20056,916,815'C-6 modified indazolylpyrrolotriazines'20056,900,206'Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives'20056,825,201'Indole, azaindole and related heterocyclic amidopiperazine derivatives'20046,750,246'C-4 carbonate taxanes'20046,476,242'2-aroyl-4-acyl paclitaxel (Taxol) analogs'20026,455,575'Phosphonooxymethyl ethers of taxane derivatives'20026,362,217'Taxane anticancer agents'20026,017,935'7-sulfur substituted paclitaxels'20005,977,386'6-thio-substituted paclitaxels'19995,912,264'6-halo-or nitrate-substituted paclitaxels'19995,773,435'Prodrugs for .beta.-lactamase and uses thereof'19985,773,461'7-deoxy-6-substituted paclitaxels'19985,773,464'C-10 epoxy taxanes'19985,693,666'6,7-modified paclitaxels'19975,646,176'Phosphonooxymethyl ethers of taxane derivatives'1997RE035524'Epipodophyllotoxin glucoside 4\'-phosphate derivatives'19975,489,589'Amino acid derivatives of paclitaxel'19965,395,849'Hybrid antitumor compounds containing a cyclic enediyne and a DNA-binder'19955,380,751'6,7-modified paclitaxels'19955,318,989'Cytotoxic bicyclo [7.3.1.]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof'19945,198,560'Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof'19935,041,424'Epipodophyllotoxin glucoside 4\'-phosphate derivatives'19914,958,010'Epipodophyllotoxin glucoside lactam derivatives'19904,904,768'Epipodophyllotoxin glucoside 4\'-phosphate derivatives'19904,874,851'3\',4\'-dinitrogen substituted epipodophyllotoxin glucoside derivatives'19894,853,467'Nitrogen containing derivatives of epipodophyllotoxin glucosides'1989

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1989Based in New Haven, CT, US· patent location history
1990–1991Based in Meriden, CT, US· patent location history
1993–2020Patents assigned to BRISTOL MYERS SQUIBB CO (111)· patent assignee history
1993–2020Based in Wallingford, CT, US· patent location history
2008–2017Patents assigned to KADOW JOHN F (29)· patent assignee history
2008–2017Patents assigned to BENDER JOHN A (15)· patent assignee history
2012–2013Patents assigned to YEUNG KAP-SUN (11)· patent assignee history
2018–2021Patents assigned to VIIV HEALTHCARE UK NO 5 LTD (12)· patent assignee history
2021Based in Branford, CT, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BRISTOL MYERS SQUIBB CO1111993–2020
KADOW JOHN Fself292008–2017
BENDER JOHN A152008–2017
VIIV HEALTHCARE UK NO 5 LTD122018–2021
YEUNG KAP-SUN112012–2013
Locations
LocationPatentsSpan
Wallingford, CT, US1281993–2020
Meriden, CT, US31990–1991
New Haven, CT, US21989
Branford, CT, US12021